Industries
Biopharmaceuticals & Rare Diseases
All research in Biopharmaceuticals & Rare Diseases — 3 reports.
38/100
Rocket Pharmaceuticals: Cash Buys Time, but Danon Still Has to Earn Back the Market's Trust
Rocket Pharmaceuticals (RCKT.US) is a rare-disease gene-therapy developer whose sole approved product, Kresladi, still generates no revenue, leaving cash and a $180 million voucher sale as the real near-term story. The stock trades near the value of its cash alone because the market still distrusts the pivotal Danon cardiac program after a 2025 clinical hold, even though Phase 1 data and a modified lower-dose cohort keep the thesis alive. Rating Hold: cash buys time, but Danon still has to earn back trust and Kresladi is too small to carry the valuation on its own.
45/100
BioMarin Pharmaceutical: A Rare-Disease Cash Engine in Transition
BioMarin is a profitable rare-disease biopharma whose enzyme franchise generated about 2.106 billion USD of 2025 revenue and funds the company, while VOXZOGO (926.9 million USD) drives both growth and sentiment. The Amicus acquisition diversified the portfolio into Fabry and Pompe disease and lifted 2026 revenue guidance to 3.825-3.925 billion USD, yet weekly and oral achondroplasia rivals from Ascendis and BridgeBio keep the margin of safety thin. Rating Hold: cash generation and Amicus diversification make BioMarin sturdier than sentiment implies, but VOXZOGO competition caps the upside at today's price.
55/100
argenx (ARGX.US / ARGX.BR): A Zen Horizon Report
argenx is the global leader in antibody therapies for rare autoimmune disease and the first-in-class pioneer of the FcRn-inhibitor field. Its core product Vyvgart (efgartigimod) is now approved across three indications (gMG, CIDP globally plus ITP in Japan), with roughly 19,000 patients on therapy, FY2025 net sales of USD 4.15 billion (+90%), and a first-ever positive operating profit of USD 1.05 billion. Vision 2030 targets 50,000 patients, 10 labels, and 5 Phase III molecules. Rating Watch: a genuinely strong asset whose USD 882.41 price already prices in smooth execution, so the entry window opens only on a pullback to USD 720 or below.